Vivanta Industries forges Strategic Pharmaceutical Partnership with Qness Pharmaceuticals

In a major step toward expanding its footprints in the healthcare sector, Vivanta Industries Limited (BSE Scrip Code: 541735, ISIN: INE299W01022) has officially entered into business collaboration agreements with domestic player Qness Pharmaceuticals. The partnership marks a calculated effort by Vivanta to deepen its commercial presence in the manufacturing, supply, and marketing of pharmaceutical and allied products.

Scope and Mechanics of the Collaboration

The partnership establishes a comprehensive domestic framework between Vivanta Industries and Qness Pharmaceuticals, which operates as a specialized proprietorship concern. Under the terms of the newly executed agreements, the two entities will collaborate on several core operational fronts:

Manufacturing and Procurement: The entities will join forces to manufacture and procure high-quality pharmaceutical products.

Branding and Distribution: The scope explicitly extends to joint branding, marketing, and distribution activities across the domestic market.

Commercial Terms: The collaboration operates on a transaction-based model. No upfront consideration has been paid or received by either party. Instead, commercial payouts and product-wise pricing will be dynamically determined based on individual purchase orders and mutually agreed-upon terms over time.

Source : Equity Bulls

Keywords

VivantaIndustries CollaborationAgreement QnessPharmaceuticals